The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Launched by KOLDING SYGEHUS · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of a protein called PCSK9 in patients with nephrotic syndrome (NS), a condition that causes high levels of protein in the urine and can lead to high cholesterol levels (hyperlipidemia). Researchers want to find out if patients with NS have higher levels of PCSK9 compared to healthy individuals and whether the amount of PCSK9 relates to how much protein is found in their urine. They will also look at kidney tissue samples to see if PCSK9 levels are increased in those with nephrotic syndrome.

To participate in this study, you need to be at least 18 years old and admitted to the Kolding Sygehus Medical Department or Emergency Department. However, you won't be able to join if you are currently being treated with PCSK9 inhibitors or have any serious health issues that could affect your participation. If you take part, you can expect to provide blood samples to measure PCSK9 levels and possibly undergo a kidney biopsy. This research could help improve our understanding of nephrotic syndrome and its effects on kidney health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years old
• • Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.
• Exclusion Criteria:
• • Refusal to give informed consent
• • Treatment with PCSK9 inhibitors
• • Any acute or chronic condition that would limit the ability of the patient to participate in the study
• • Control group: proteinuria